Radiopharm Theranostics Ltd (ASX:RAD) has entered into a clinical supply agreement with SHINE Technologies, a next-generation fusion technology company.
RAD, a developer of radiopharmaceutical products for diagnostic and therapeutic uses, has arranged with SHINE to supply isotope non-carrier-added lutetium-177 (Lu-177).
The isotope will be used by Radiopharm to help develop its clinical pipeline of diagnostic and therapeutic radiopharmaceutical products.
Lu-177 is an important isotope utilised in multiple programs across Radiopharm’s portfolio.
Shining a light on the cancer fight
“One way or another, nearly everyone has been affected by cancer. SHINE’s efforts in lutetium-177 are all about prolonging the lives of those affected most directly,” general manager of SHINE’s Therapeutics Division Chris Vessell said.
“We are excited that our isotopes will play a critical role in Radiopharm Theranostics’ programs that aim to revolutionise cancer treatment.”
SHINE is an emerging leader in the production of this medical radioisotope and intends to be the industry’s only vertically integrated producer of Lu-177, aiming to provide a reliable and scalable supply independent of current supply-chain restraints.
SHINE and RAD are highly complementary, with the latter doing what it can to continue the development of its clinical programs.
“Ensuring supply of key isotopes continues to be a priority for our team, allowing us to accelerate our clinical programs unimpeded,” Radiopharm Theranostics CEO and managing director Riccardo Canevari said.
“Lutetium-177 is required for three of our more advanced assets and this clinical supply agreement with SHINE, an experienced player in nuclear technology, is another important step in de-risking our business plan.”
SHINE’s proprietary isotope production processes create both molybdenum-99 and n.c.a. Lu-177, each of which are used in multiple diagnostic and therapeutic medical procedures.